AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
On Thursday, AstraZeneca Plc AZN reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant currency), beating the consensus of $14.29 billion.
AstraZeneca: China exposure manageable, says investment bank
AstraZeneca PLC (LSE:AZN) could face a fine of up to £4.5 million as the Chinese authorities investigate allegedly illegal imports of cancer drugs Imfinzi and Imjudo. The Shenzhen City Customs suspects $0.9 million in unpaid import taxes, with AstraZeneca estimating fines could be one to five times that amount.
AstraZeneca receives £6bn boost as earnings beat forecasts
AstraZeneca PLC (LSE:AZN) shares climbed 3.5% in early trading, adding £6 billion to its market value, after reporting strong annual profits driven by its cancer, lung, and immunology treatments. Revenue for 2024 grew 21% to $54.1 billion (£43 billion), while pre-tax profit jumped 38% to $8.7 billion on a constant currency basis.
AstraZeneca 2025 sales outlook tops expectations
AstraZeneca forecast its 2025 sales above analysts' expectations on Thursday, after the drugmaker's fourth-quarter revenue beat estimates, driven by robust demand, especially for its medicines for cancer and heart diseases.
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.
UK hits back at AstraZeneca over collapse of investment deal
Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, resulting in a lower offer of government support.
Seeking Clues to Astrazeneca (AZN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
AstraZeneca dips after shelving UK investment plans
AstraZeneca PLC (LSE:AZN) shares fell slightly on Monday after reports that it had shelved a £450 million vaccine manufacturing plant extension in northwest England, turning down £80 million of government support. In co-announced plans last year, the FTSE 100's largest company said it would plough £650 million into a vaccine manufacturing facility in Liverpool alongside the expansion of an existing site in Cambridge, dependent on a "mutual agreement" with HM Treasury and other parties.
AstraZeneca ditches plan to build $558 mln UK vaccine plant
AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.
AstraZeneca and GSK put spotlight on pharma as results loom
AstraZeneca PLC and GSK PLC will bring the pharmaceutical sector into the spotlight when both report next week. For AstraZeneca, full-year figures on Thursday, February 6 come after its shares have receded from an all-time high in August.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.
